Fundraising Fox
🦊/Companies
Sign in

Fore Biotherapeutics

Philadelphia, US · 55 employees on LinkedIn · 8 known investors

Find your way into Fore Biotherapeutics

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.

BiotechHealthtechMedical Devices

Investors · 8

LG Technology VenturesSanta Clara
Novartis Venture FundBasel · $5M – $25M
OrbiMedNew York · $1M – $75M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
SR One Capital ManagementRedwood City
Windham Capital PartnersNew York · $1M – $5M
MedicxireportedLondon
SymBiosisreportedBentonville

Funding

SEC filings, press & company announcements

$67.4M disclosed across 1 of 2 rounds · 2026

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap
Fortress Biotech29 shared keywordsFortress Biotech is a biopharmaceutical company that acquires and advances assets across therapeutic areas including oncology, dermatology, and rare diseases, generating value through product revenue, equity holdings, and dividend and royalty income. The company operates a portfolio of marketed prescription pharmaceutical products and development programs through majority-owned subsidiaries and minority ownership positions in partner companies.

Companies competing with Fore Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Fore Biotherapeutics lands $67M extension to support ongoing cancer drug developmenttechnical.ly · Aug 2026FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Fundingfinsmes.com · Jul 2026Fore Biotherapeutics secures $67M in one of year's largest biotech funding rounds - Philadelphia Business Journalbizjournals.com · Jul 2026The Fore’s Funding Programme Opens for Registration on 25 March — Supporting Communitiessupportingcommunities.org · Mar 2026Apply for funding - The Forethefore.org · Feb 2023Who we fund - The Forethefore.org · Oct 2019

Frequently asked questions

What does Fore Biotherapeutics do?
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.
Who are Fore Biotherapeutics's investors?
Fore Biotherapeutics's investors include LG Technology Ventures, Novartis Venture Fund, OrbiMed, Pontifax Venture Capital, SR One Capital Management, Windham Capital Partners, Medicxi, SymBiosis.
How much funding has Fore Biotherapeutics raised?
Fore Biotherapeutics has disclosed $67.4M raised across 1 of its 2 known rounds.
Where is Fore Biotherapeutics headquartered?
Fore Biotherapeutics is headquartered in Philadelphia, US.